A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer

Published:2017-04 Issue:2 Volume:15 Page:196-202.e1
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Ho Thai H.,Nunez-Nateras Rafael,Hou Yue-Xian,Bryce Alan H.,Northfelt Donald W.,Dueck Amylou C.,Wong Bryan,Stanton Melissa L.,Joseph Richard W.,Castle Erik P.

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference37 articles.

1. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years;Iversen;BJU Int,2010

2. Secondary hormonal therapy for advanced prostate cancer;Lam;J Urol,2006

3. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials;Lancet,2000

4. Estrogen receptor beta expression and androgen receptor phosphorylation correlate with poor clinical outcome in hormone-naive prostate cancer and are elevated in castration resistant disease;Zellweger;Endocr Relat Cancer,2013

5. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer;Setlur;J Natl Cancer Inst,2008

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of an Estrogen Receptor α-Selective 18F-Estradiol PET Tracer;World Journal of Nuclear Medicine;2024-06-18

2. Nuclear Estrogen Receptors in Prostate Cancer: From Genes to Function;Cancers;2023-09-20

3. The Role of ERα and ERβ in Castration-Resistant Prostate Cancer and Current Therapeutic Approaches;Biomedicines;2023-03-09

4. Prostate cancer in transgender women: considerations for screening, diagnosis and management;British Journal of Cancer;2022-10-19

5. Selective estrogen receptor modulators contribute to prostate cancer treatment by regulating the tumor immune microenvironment;Journal for ImmunoTherapy of Cancer;2022-04